the receptor binding domain of mers-cov: the dawn of vaccine and treatment development
Clicks: 183
ID: 188657
2014
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
30.0
/100
182 views
19 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) is becoming another “SARS-like” threat to the world. It has an extremely high death rate (∼50%) as there is no vaccine or efficient therapeutics. The identification of the structures of both the MERS-CoV receptor binding domain (RBD) and its complex with dipeptidyl peptidase 4 (DPP4), raises the hope of alleviating this currently severe situation. In this review, we examined the molecular basis of the RBD-receptor interaction to outline why/how could we use MERS-CoV RBD to develop vaccines and antiviral drugs.
| Reference Key |
zhou2014journalthe
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Nan Zhou;Yun Zhang;Jin-Chun Zhang;Ling Feng;Jin-Ku Bao |
| Journal | Bioorganic & medicinal chemistry letters |
| Year | 2014 |
| DOI |
10.1016/j.jfma.2013.11.006
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.